INVESTOR RELATIONS
Successful rights issue strengthens the company’s position
Second quarter 20255 | CEO’s comment
”With a strengthened financial position, we can now fully focus on what is central – driving clinical development forward at a rapid pace so that we can achieve our goal: for arfolitixorin to reach the market and help hundreds of thousands of cancer patients achieve better treatment outcomes,” says CEO, Petter Segelman Lindqvist.
INVESTORS – latest reports and presentations
Q2 2025
Presentations
Media – Lates pressreleases
Isofol Medical AB (publ) publishes interim report, January–June 2025
GOTHENBURG, Sweden, August 26, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2025 is…
Isofol invites to a presentation of the interim report for the second quarter 2025
GOTHENBURG, Sweden, August 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors, analysts and media to a webcast presentation and…
New number of shares and votes in Isofol
GOTHENBURG, Sweden, July 31, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces new number of shares and votes in the company.The information…

SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS
About arfolitixorin
Want to know more about the the drug candidate arfolitxorin?
Last updated 09-16-2025